GentiBio Revenue and Competitors
Estimated Revenue & Valuation
- GentiBio's estimated annual revenue is currently $15.8M per year.
- GentiBio's estimated revenue per employee is $155,000
- GentiBio's total funding is $177M.
Employee Data
- GentiBio has 102 Employees.
- GentiBio grew their employee count by -7% last year.
GentiBio's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-founder and CEO | Reveal Email/Phone |
2 | Co-founder and VP, R&D Operations | Reveal Email/Phone |
3 | Head Technical Development Operations | Reveal Email/Phone |
4 | VP Business Development | Reveal Email/Phone |
5 | Head People | Reveal Email/Phone |
6 | VP Finance | Reveal Email/Phone |
7 | VP Translational Science | Reveal Email/Phone |
8 | Associate Director, Research and HQ Operations | Reveal Email/Phone |
9 | Senior Director, CMC Lifecycle Management | Reveal Email/Phone |
10 | Senior Director Program Management | Reveal Email/Phone |
GentiBio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is GentiBio?
GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.
keywords:N/A
$177M
Total Funding
102
Number of Employees
$15.8M
Revenue (est)
-7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
GentiBio News
Rawlings is a co-founder of preclinical biotech company Gentibio, which is also developing regulatory T cell therapies for type 1 diabetes...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $23.9M | 102 | -3% | N/A |
#2 | $16.8M | 102 | N/A | N/A |
#3 | $13.3M | 102 | 0% | N/A |
#4 | $15.8M | 102 | 55% | N/A |
#5 | $18.4M | 102 | 24% | N/A |